Formulations of PTHrP analogs, transdermal patches thereof, and uses thereof

The invention relates to the field of osteoporosis treatment, in particular to a preparation of a PTHrP analogue, a transdermal patch of the PTHrP analogue and application of the PTHrP analogue, and the prepared preparation comprises a therapeutic active substance, water and one or more excipients selected from Zn < 2 + > salt, Mg < 2 + > salt, Ca < 2 + > salt, polyethylene glycol and hydroxypropyl beta-cyclodextrin. The present invention relates to a PTHrP analogue formulation for transdermal delivery of a therapeutically effective amount of a PTHrP analogue, and methods of treating osteoporosis, osteopenia, osteoarthritis and/or fractures, improving bone mineral density (BMD), improving trabecular bone score (TBS), and treating, preventing and/or reducing fractures using these formulations and patches..

Medienart:

Patent

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Europäisches Patentamt - (2022) vom: 09. Sept. Zur Gesamtaufnahme - year:2022

Sprache:

Englisch

Beteiligte Personen:

HATTERSLEY GARY [VerfasserIn]
HARRIS ALAN [VerfasserIn]
SAJE JAMAL [VerfasserIn]
HAMED EHAB [VerfasserIn]
K BROWN [VerfasserIn]
DOMMEL DIETER [VerfasserIn]
MOSEMANN J ¨ 1 RGEN [VerfasserIn]
ZHANG YI [VerfasserIn]
DEAK LAUREN [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2022-09-09, Last update posted on www.tib.eu: 2024-02-26, Last updated: 2024-03-01

Patentnummer:

CN115025068

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA015487814